Pertuzumab zuvotolimod

Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) , a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research[1].

2500674-05-3

SBT6050

12352203

Antibody-Drug Conjugates (ADCs) ; EGFR; Toll-like Receptor (TLR)

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Cancer; Inflammation/Immunology

H2O

[Pertuzumabzuvotolimod]

[1]Metz H, et al. SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist[J]. 2020.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P9994/

Inhibitory Antibodies

No Development Reported